1 Test - 10 Cancers - Unlimited Possibilities
Our next-generation test, Aristotle®, is a panel for simultaneously screening for 10 cancers from a single sample of blood. Aristotle has been built on our proprietary mRNA technology platform, which was validated in more than 10,000 patients for the development of the first liquid biopsy for Colorectal Cancer (ColonSentry®).
Early Results Show that Aristotle has a high Sensitivity and Specificity across multiple cancers
Colorectal, Prostate, Cervical, Endometrial, Breast, Ovarian, Liver, Bladder, Nasopharyngeal, and Stomach Cancer.
The multi-cancer panel platform, Aristotle, has been demonstrated to identify sets of gene transcripts capable of classifying subjects as having a specific cancer with a high degree of sensitivity and specificity. Early validation was conducted using blood samples from 788 subjects across 10 cancer types and 2,064 subjects without cancer.
|
“StageZero Life Sciences, one of the pioneers of the liquid biopsy, has developed the 'holy-grail' – a suite of tests that have the correct sensitivity and specificity to detect cancer early and perform correctly as a screening tool at the population level." Dietrich Stephan CEO and Founder, LifeXVentures™ Professor of Human Genomics |
Aristotle’s 2-fold Cross Validation & Accuracy
These graphs demonstrate Aristotle's high Sensitivity and Specificity on ten cancers.
|
|
|
The First Multi-Cancer Detection Panel for Women For years, the healthcare community has been searching for a test that can find Ovarian cancer early. In fact 80% of ovarian cancers are found in the later stages. We're out to change that, not just for ovarian cancer, but for 9 of the most prevalent cancers affecting women today. 1 Sample of Blood - 9 Cancers - Found Early.
|
|
A multi-cancer detection panel for men is in development
|
Looking Beyond Cancer
Our scientists are also looking to apply Aristotle to disease states in Gastroenterology, Neurology, Cardiology, and Autoimmune Disorders.
|
